News

Quigley has reported the results from its phase IIb double-blind, placebo-controlled, study of topical compound QR-333. It is intended for the treatment of symptomatic diabetic peripheral neuropathy. The

Sinovac has initiated dosing in its clinical trial of various Panflu vaccine candidates for pandemic influenza A (H1N1). Reportedly, three types of vaccines, including split viron vaccine, split

FDA has extended the review of Takeda’s New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS (pioglitazone HCl). Reportedly, the NDA for the FDC

GlaxoSmithKline (GSK) has completed its acquisition of Stiefel. The company has acquired the total share capital of Stiefel for a cash consideration of $2.9 billion. Under the terms

Human Genome Sciences has reported that the net loss for the second quarter ended June 30, 2009, decreased to $65.4 million or $0.48 per share, compared to a

PSS World Medical, a distributor of medical products, has witnessed an increase of sales by 4.5% for the fiscal 2010 first quarter ended June 26, 2009. The company

Bayer Technology Services has developed a new process for the purification of acetonitrile (ACN). The four-step process now enables ACN feed stock to be purified on the ton

Alexion Pharmaceuticals, engaged in the discovery, development and commercialization of therapeutic products, has reported a 55% increase in revenue for its second quarter ended June 30, 2009. The

Conceptus has reported financial results for the three and six months ended June 30, 2009. Net sales for the second quarter of 2009 were $33 million, an increase